IMAGING SYSTEM AND METHOD OF PRODUCING IMAGING SYSTEMS BASED ON NANOPARTICLES AND USE THEREOF TO INCREASE EFFICIENCY OF RADIOLOGICAL METHODS OF INVESTIGATING MALIGNANT NEOPLASMS Russian patent published in 2024 - IPC A61K49/04 A61K49/06 A61K49/18 B82Y5/00 B82Y40/00 

FIELD: nanomedicine.

SUBSTANCE: group of inventions relates to a method for preparing a composition from nanoparticles and use of such a composition in diagnosing malignant neoplasms. Method for preparing a composition for use in imaging systems for radiological research methods involves synthesis of barium carbonate nanoparticles, wherein the following solutions are first obtained: polyacrylic acid in an ethylene glycol solution; sodium carbonate in ethylene glycol solution; barium chloride in ethylene glycol solution. Polyacrylic acid solution is mixed with sodium carbonate solution, mixed, while bringing pH of solution to 3–5; polyacrylic acid solution is mixed with barium chloride solution and stirred, while bringing the solution pH to 3–5. Mixed polyacrylic acid/sodium carbonate solution is added to the mixing polyacrylic acid/barium chloride solution drop-by-drop for 1–10 minutes, the final solution is stirred for 0.5–2 hours, after which the obtained barium carbonate nanoparticles are washed: 2–5 cycles of washing with ethanol and 3–6 cycles of washing with distilled water. Obtained precipitate of barium carbonate nanoparticles (BaCO₃) is lyophilised to obtain a composition. Composition obtained using said method contains barium carbonate nanoparticles, which are biodegradable/biocompatible spherical nanoparticles, the maximum size of which is 100 nm. Composition is used for imaging malignant growths in radiological methods by introducing an effective amount of nanoparticles into the malignant growths.

EFFECT: obtaining agents providing contrast enhancement in radiological research methods, based on nanoparticles, which have spherical morphology for distribution in bloodstream and inside tissues of organs, high aggregative stability in biological media, good biocompatibility, optimal pharmacokinetic parameters and physical and chemical characteristics, as well as improved ability to attenuate X-rays in comparison with commercially available X-ray contrast agents used in clinical practice.

4 cl, 2 ex, 5 dwg